Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIMOLIDE 10-25 vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Timolol is extensively metabolized in the liver primarily by CYP2D6; hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Timolol is approximately 10-60% bound to plasma proteins (primarily albumin). Hydrochlorothiazide is about 40-70% bound to plasma proteins.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Timolol: Vd approximately 1.3-3.6 L/kg, indicating extensive tissue distribution. Hydrochlorothiazide: Vd approximately 0.8-1.2 L/kg.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability of timolol is approximately 50-75% due to first-pass metabolism. Hydrochlorothiazide bioavailability is about 65-70%. Ophthalmic timolol undergoes systemic absorption, with measurable plasma levels.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-50 m L/min: maximum dose of timolol 10 mg/hydrochlorothiazide 25 mg once daily. GFR <30 m L/min: contraindicated (hydrochlorothiazide ineffective, risk of thiazide accumulation).
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose; start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg) and titrate cautiously. Child-Pugh C: contraindicated (risk of hepatic encephalopathy and beta-blocker toxicity).
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended; safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg once daily); monitor renal function, electrolytes, and heart rate. Avoid in patients with significant bradycardia or heart block.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
No FDA black box warning.
None
Exacerbation of angina or myocardial ischemia upon abrupt withdrawal,Bronchospasm in patients with asthma or COPD,Masking of hypoglycemia in diabetic patients,Electrolyte imbalances, hypokalemia, hypercalcemia, hyperuricemia due to hydrochlorothiazide,Fetal harm if used during pregnancy
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Overt cardiac failure,Anuria,Hypersensitivity to timolol or hydrochlorothiazide
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) as hydrochlorothiazide can cause potassium loss, but timolol may mask hyperkalemia. Limit salt intake to enhance blood pressure control. Consume alcohol moderately as it may potentiate hypotension. Take with food to reduce gastrointestinal upset.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. Thiazides may cause fetal electrolyte imbalances and jaundice. Second and third trimesters: Continued risk of fetal bradycardia, reduced placental perfusion, and neonatal complications (hypoglycemia, bradycardia, respiratory depression). Thiazides may cause oligohydramnios and neonatal thrombocytopenia.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Timolol is excreted into breast milk (M/P ratio approximately 1.4). Hydrochlorothiazide is also present in low amounts. Due to potential for infant bradycardia, hypoglycemia, and electrolyte disturbances, use during breastfeeding is generally not recommended. If essential, monitor infant for signs of beta-blockade and thiazide effects.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Pregnancy may alter pharmacokinetics of timolol due to increased plasma volume and renal clearance. Hydrochlorothiazide efficacy may be reduced due to increased GFR. Dose adjustments should be guided by clinical response but no standard dose modification; use lowest effective dose.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Timolide 10-25 contains timolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor heart rate and blood pressure closely due to risk of bradycardia and hypotension. Avoid abrupt discontinuation to prevent rebound hypertension. Use with caution in patients with asthma, COPD, or diabetes as beta-blockers can mask hypoglycemia. Check electrolytes and renal function periodically due to diuretic effects.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this drug suddenly; consult your doctor before discontinuing to avoid a rapid rise in blood pressure.,Notify your doctor if you experience slow heartbeat, dizziness, fainting, or signs of electrolyte imbalance (e.g., muscle cramps, weakness, irregular heartbeat).,Avoid alcohol as it may increase dizziness or drowsiness.,Use caution when driving or operating machinery until you know how this medication affects you.,Keep all appointments for blood pressure and lab tests (e.g., potassium, sodium, kidney function).
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIMOLIDE 10-25 vs ALDORIL D30, answered by our medical review team.
TIMOLIDE 10-25 is a Antihypertensive Combination that works by Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIMOLIDE 10-25 and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIMOLIDE 10-25 is: One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIMOLIDE 10-25 and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIMOLIDE 10-25 is classified as Category C. First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. T. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.